Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
NCT ID: NCT05888129
Last Updated: 2023-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1 participants
OBSERVATIONAL
2017-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
NCT01458717
Surgical Results of Resection of Locally Advanced Pancreatic Cancer
NCT06206382
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
NCT06129812
Multimodal Therapy Impact on Pancreatic Cancer Survival
NCT06938906
Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer
NCT04110769
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
locally advanced pancreatic cancer
Locally advanced pancreatic cancer (LA-PC) is classified according to the National Comprehansive Cancer Networks (NCCN) guidelines.
Patients with the above conditions underwent surgery after neoadjuvant chemotherapy.
surgery after neoadjuvant chemotherapy
surgery after neoadjuvant chemotherapy
borderline resectable pancreatic cancer
Borderline resectable pancreatic cancer (BR-PC) is classified according to the NCCN guidelines.
Patients with the above conditions underwent surgery after neoadjuvant chemotherapy.
surgery after neoadjuvant chemotherapy
surgery after neoadjuvant chemotherapy
resectable pancreatic cancer
Resectable pancreatic cancer (PC) is classified according to the NCCN guidelines.
There are no arterial and venous contact with tumor Patients with the above conditions underwent upfront surgery
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
surgery after neoadjuvant chemotherapy
surgery after neoadjuvant chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Song Cheol Kim
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Song Cheol Kim, MD. PhD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan medical center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-0902
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.